Lexaria regains Nasdaq minimum bid price compliance; plans reverse split meeting

Lexaria Bioscience Corp.

Received Nasdaq letter confirming bid price >=$1.00 for 10 consecutive days through Aug 23, 2023.
Regained compliance with Nasdaq Listing Rule 5550(a)(2) for continued listing.
Company called special meeting to approve possible reverse stock split by May 31, 2024.
Intends to proceed with reverse split proposal to enable quick future compliance and attract investment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.